(Reuters Health)—U.S. commercial health plans only covered biosimilar treatments as preferred products in 14% of coverage decisions last year, according to an analysis of publicly available data on coverage decisions.1 Researchers examined records from the Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database, which has information on coverage decisions made by 17 of…
Search results for: biosimilars

Rheumatology Biologic Expertise Valued for COVID-19 Treatment Decisions
At the Loma Linda University Medical Center, Calif., rheumatologists play a key consulting role for COVID-19 patients who may benefit from the use of biologic treatments…

The Nebraska Rheumatology Society Grows to Meet State’s Challenges
As state rheumatology societies go, the Nebraska Rheumatology Society (NRS) is one of the new kids on the block. Established two years ago, the NRS hopes to involve all 27 rheumatologists across the state. Marcus Snow, MD, a rheumatologist at the University of Nebraska Medical Center (UNMC), Omaha, says the state’s rheumatologists are spread across…

Rheumatoid Arthritis Therapy Update: What’s Changed & What’s the Same
SNOWMASS VILLAGE, COLO.—Current trends in rheumatoid arthritis (RA) therapy are the increased use of newer medication categories, such as Janus kinase (JAK) inhibitors (Jakinibs) and biologics, and the rising costs of treatment. Unchanged is the consistent use of methotrexate as an effective therapy. These topics and more were discussed at the ACR Winter Symposium during…

Yes, the FDA Employs Rheumatologists. Here’s Their Role.
Ever wonder what role physician regulators—rheumatologists, in particular—perform at the U.S. Food & Drug Administration (FDA)? “I am not sure that many practicing rheumatologists know there are clinicians who work for the FDA,” says rheumatologist Nadia Habal, MD, a medical officer in the Division of Pulmonary, Allergy, and Rheumatology Products at the FDA. “It would…

Experts Discuss Current Insurance Issues Challenging Rheumatology
ATLANTA—From step therapy requirements to infusion center locations to evaluation and management coding, insurance issues bring frequent headaches to clinicians and patients. Experts discussed some of the most recent concerns in a session at the 2019 ACR/ARP Annual Meeting. Chris Phillips, MD, chair of the ACR’s Insurance Subcommittee (ISC), and Gary Bryant, MD, delegate to…

Range of Insurance Issues Challenge Rheumatology
ACR representatives updated members on recent insurance issues…
Biologic Spending & Price Trends
Any given rheumatology patient who needs a biologic disease-modifying anti-rheumatic drug (DMARD) will spend $22,000–44,000 on their medication each year…
ACR Advocacy: 2019 Year in Review
As a new year begins, Government Affairs Committee chair Blair Solow, MD, takes stock of ACR advocacy wins in 2019 and issues to watch in 2020.

Coding Corner Answers: Rheumatology Word Search
Take the challenge. Answers Biosimilars Methotrexate Time Presenting problem Ultrasound guidance International Classification of Diseases Current Procedural Terminology Trigger points Osteoporosis Osteoarthritis
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 32
- Next Page »